


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A compound of the general formula (I)




wherein

R<sup>1</sup> is selected from

hydrogen, a branched or straight C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>4</sub>-C<sub>8</sub>(alkyl-cycloalkyl) wherein alkyl is C<sub>1</sub>-C<sub>2</sub> alkyl and cycloalkyl is C<sub>3</sub>-C<sub>6</sub> cycloalkyl;

C<sub>6</sub>-C<sub>10</sub> aryl; or heteroaryl having from 5 to 10 atoms selected from any of C, S, N and O; wherein the aryl and heteroaryl may optionally and independently be substituted by 1 or 2 substituents independently selected from any of hydrogen, CH<sub>3</sub>, (CH<sub>2</sub>)<sub>p</sub>CF<sub>3</sub>, halogen, CONR<sup>5</sup>R<sup>4</sup>, COOR<sup>5</sup>, COR<sup>5</sup>, (CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>R<sup>4</sup>, (CH<sub>2</sub>)<sub>p</sub>CH<sub>3</sub>(CH<sub>2</sub>)<sub>p</sub>SOR<sup>5</sup>R<sup>4</sup>, (CH<sub>2</sub>)<sub>p</sub>SO<sub>2</sub>R<sup>5</sup>, (CH<sub>2</sub>)<sub>p</sub>SO<sub>2</sub>NR<sup>5</sup> and (CH<sub>2</sub>)<sub>p</sub>OR<sup>5</sup>, wherein ~~R<sup>4</sup> and R<sup>5</sup> is each and independently as defined for R<sup>1</sup> above~~ and p is 0, 1 or 2;


(C<sub>1</sub>-C<sub>2</sub> alkyl)-(C<sub>6</sub>-C<sub>10</sub> aryl); or (C<sub>1</sub>-C<sub>2</sub> alkyl)heteroaryl, the heteroaryl moieties having from 5 to 10 atoms selected from any of C, S, N and O, and where the aryl or heteroaryl may optionally and independently be substituted by 1 or 2 substituents independently selected from any of hydrogen, CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>q</sub>CF<sub>3</sub>, halogen, -CONR<sup>5</sup>R<sup>4</sup>, -COOR<sup>5</sup>, -COR<sup>5</sup>, -(CH<sub>2</sub>)<sub>q</sub>NR<sup>5</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>q</sub>CH<sub>3</sub>(CH<sub>2</sub>)<sub>q</sub>SOR<sup>5</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>q</sub>SO<sub>2</sub>R<sup>5</sup>, -(CH<sub>2</sub>)<sub>q</sub>SO<sub>2</sub>NR<sup>5</sup>, and -(CH<sub>2</sub>)<sub>p</sub>OR<sup>5</sup> wherein ~~R<sup>4</sup> and R<sup>5</sup> is each and independently as defined for R<sup>1</sup> above~~ and q is 0, 1 or 2; and



wherein  $R^{18}$ ,  $R^{19}$ ,  $R^{20}$ ,  $R^{21}$ ,  $R^{22}$ ,  $R^{23}$ ,  $R^{24}$  and  $R^{25}$  is each and independently hydrogen,  $C_1$ - $C_6$  alkyl or  $C_1$ - $C_6$  alkenyl;

$R^2$  and  $R^3$  is each and independently hydrogen or  $C_1$ - $C_6$  alkyl;

A is selected from



wherein  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $R^{11}$ ,  $R^{12}$ ,  $R^{13}$ ,  $R^{14}$ ,  $R^{15}$ ,  $R^{16}$  and  $R^{17}$  is each and independently as defined for  $R^1$  below, and wherein the phenyl ring of each A substituent may be optionally and independently substituted by 1 or 2 substituents  $Z^1$  and  $Z^2$  selected from hydrogen,  $CH_3$ ,  $-(CH_2)_qCF_3$ , halogen,  $-CONR^6R^7$ ,  $-CO_2R^6$ ,  $-COR^6$ ,  $-(CH_2)_rNR^6R^7$ ,  $-(CH_2)_rCH_3(CH_2)_rSOR^6$ ,  $-(CH_2)_rSO_2R^6$  and  $-(CH_2)_rSO_2NR^6R^7$  wherein  $R^6$  and  $R^7$  is each and independently as defined for  $R^1$  above and  $r$  is 0, 1, or 2;

Q is  $C_5$ - $C_6$  hydroaryl or heterohydroaromatic having 5 or 6 atoms selected from anyone of C, S, N and O;  $C_5$ - $C_6$  cycloalkyl, or heterocycloalkyl having 5 or 6 atoms selected from any one of C, N, O and S; and where each Q may optionally be substituted by a substituent  $Z^1$  and  $Z^2$  as defined above;

B is


~~selected from phenyl, naphthyl, a substituted or unsubstituted aromatic, heteroaromatic, hydroaromatic or heterohydroaromatic moiety having from 5 to 10 atoms selected from any of C, S, N and O, optionally and independently substituted by 1 or 2 substituents independently selected from hydrogen, CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>t</sub>CF<sub>3</sub>, halogen, -(CH<sub>2</sub>)<sub>t</sub>CONR<sup>5</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>t</sub>NR<sup>5</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>t</sub>COR<sup>5</sup>, -(CH<sub>2</sub>)<sub>t</sub>COOR<sup>5</sup>, -OR<sup>5</sup>, -(CH<sub>2</sub>)<sub>t</sub>SOR<sup>5</sup>, -(CH<sub>2</sub>)<sub>t</sub>SO<sub>2</sub>R<sup>5</sup>, and -(CH<sub>2</sub>)<sub>t</sub>SO<sub>2</sub>NR<sup>5</sup>R<sup>4</sup>, wherein R<sup>4</sup> and R<sup>5</sup> is each and independently as defined for R<sup>1</sup> above, and t is 0, 1, 2 or 3; and~~

~~R<sup>4</sup> and R<sup>5</sup>, R<sup>6</sup>, and R<sup>7</sup>, is each and independently selected from hydrogen, a branched or straight C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>1</sub>-C<sub>6</sub> alkenyl, C<sub>3</sub>-C<sub>8</sub> cycloalkyl, C<sub>4</sub>-C<sub>8</sub>(alkyl-cycloalkyl) wherein alkyl is C<sub>1</sub>-C<sub>2</sub> alkyl and cycloalkyl is C<sub>3</sub>-C<sub>6</sub> cycloalkyl as defined for R<sup>1</sup> above;~~

as well as pharmaceutically acceptable salts of the compounds of the formula (I), and isomers, hydrates, isoforms and prodrugs thereof.

2. (currently amended) A compound of the formula (I) according to claim 1, wherein

A is selected from



wherein ~~R<sup>8</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>14</sup>, R<sup>15</sup>, R<sup>16</sup> and R<sup>17</sup> is each and independently as defined for R<sup>1</sup> above, and~~ wherein the phenyl ring of each A substituent may be optionally and independently substituted at any position of the phenyl ring by 1 or 2 substituents Z<sup>1</sup> and Z<sup>2</sup> which are each and independently selected from hydrogen, CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>q</sub>CF<sub>3</sub>, halogen, -CONR<sup>6</sup>R<sup>7</sup>, -COOR<sup>6</sup>, -COR<sup>6</sup>, -(CH<sub>2</sub>)<sub>r</sub>NR<sup>6</sup>R<sup>7</sup>, -(CH<sub>2</sub>)<sub>r</sub>CH<sub>3</sub>(CH<sub>2</sub>)<sub>r</sub>SOR<sup>6</sup>, -(CH<sub>2</sub>)<sub>r</sub>SO<sub>2</sub>R<sup>6</sup> and -(CH<sub>2</sub>)<sub>r</sub>SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup> wherein ~~R<sup>6</sup> and R<sup>7</sup> is each and independently as defined for R<sup>1</sup> above, and~~ r is 0, 1, or 2;

Q is selected from morpholine, piperidine and pyrrolidine;

~~R<sup>1</sup>, R<sup>4</sup>, and R<sup>5</sup> is each and independently~~ selected from hydrogen, a branched or straight C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>3</sub>-C<sub>5</sub> cycloalkyl, C<sub>4</sub>-C<sub>8</sub> (alkyl-cycloalkyl) wherein alkyl is C<sub>1</sub>-C<sub>2</sub> alkyl and cycloalkyl is C<sub>3</sub>-C<sub>6</sub> cycloalkyl; C<sub>6</sub>-C<sub>10</sub> aryl; and heteroaryl having from 5 to 6 atoms selected from any of C, S, N and O; and where the aryl or heteroaryl may optionally and independently be substituted by 1 or 2 substituents independently selected from any of hydrogen, CH<sub>3</sub>, -(CH<sub>2</sub>)<sub>p</sub>CF<sub>3</sub>, halogen, -CONR<sup>5</sup>R<sup>4</sup>, -COOR<sup>5</sup>, -COR<sup>5</sup>, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>p</sub>CH<sub>3</sub>(CH<sub>2</sub>)<sub>p</sub>SOR<sup>5</sup>R<sup>4</sup>, -(CH<sub>2</sub>)<sub>p</sub>SO<sub>2</sub>R<sup>5</sup>, and -


$(\text{CH}_2)_p\text{SO}_2\text{NR}^5$ , wherein  ~~$\text{R}^4$  and  $\text{R}^5$  is each and independently as defined for  $\text{R}^4$  above~~ and  $p$  is 0, 1 or 2;




$B$  is selected from phenyl, and naphthyl, indolyl, benzofuranyl, dihydrobenzofuranyl, benzothiophenyl, pyrrol, furanyl, quinolinyl, isoquinolinyl, cyclohexyl, cyclohexenyl, cyclopentyl, cyclopentenyl, indanyl, indenyl, tetrahydronaphthyl, tetrahydroquinyl, tetrahydroisoquinolinyl, tetrahydrofuranlyl, pyrrolidinyl, and indazolyl, each optionally and independently substituted by 1 or 2 substituents independently selected from hydrogen,  $\text{CH}_3$ ,  $\text{CF}_3$ , halogen,  $-(\text{CH}_2)_q\text{CONR}^5\text{R}^4$ ,  $-(\text{CH}_2)_q\text{NR}^5\text{R}^4$ ,  $-(\text{CH}_2)_q\text{COR}^5$ ,  $-(\text{CH}_2)_q\text{CO}_2\text{R}^5$ , and  $-\text{OR}^5$ ; wherein  $q$  is 0 or 1, and wherein  $\text{R}^4$ ,  $\text{R}^5$ ,  $\text{R}^6$ , and  $\text{R}^7$ , is each and independently selected from hydrogen, a branched or straight  $\text{C}_1$ - $\text{C}_6$  alkyl,  $\text{C}_1$ - $\text{C}_6$  alkenyl,  $\text{C}_3$ - $\text{C}_8$  cycloalkyl,  $\text{C}_4$ - $\text{C}_8$ (alkyl-cycloalkyl) wherein alkyl is  $\text{C}_1$ - $\text{C}_2$  alkyl and cycloalkyl is  $\text{C}_3$ - $\text{C}_6$  cycloalkyl ~~$\text{R}^4$  and  $\text{R}^5$  are as defined above;~~




$\text{R}^2$  and  $\text{R}^3$  is each and independently hydrogen or methyl.




3. (canceled)

4. (currently amended) A compound of the formula (I) according to claim 1, which compound is any of




























wherein R is morpholine, piperidine or pyrrolidine;





15. (currently amended) A compound according to ~~any of claim 1-7~~ claim 1-7, further characterised in that it is isotopically labelled.

16. (canceled).

17. (original) An isotopically labelled compound of the formula (I) of claim 1.

18. (canceled).

19. (original) A pharmaceutical composition comprising a compound of the formula (I) according to claim 1 as an active ingredient, together with a pharmacologically and pharmaceutically acceptable carrier.

20-26. (canceled)